CAR T Cells: Second-Line Treatment Option for NHL? - NCI
By A Mystery Man Writer
Recent trial results suggest that CAR T cells may be superior to standard treatments for B-cell NHL that has not responded or has returned after treatment.
Frontiers The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions
Tumor buster - where will the CAR-T cell therapy 'missile' go?, Molecular Cancer
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL - ScienceDirect
Non-viral precision T cell receptor replacement for personalized cell therapy
T-cell therapies for T-cell lymphoma - Cytotherapy
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
media.springernature.com/m685/springer-static/imag
Tumor buster - where will the CAR-T cell therapy 'missile' go?, Molecular Cancer
JPM, Free Full-Text
CAR T Cells: Second-Line Treatment Option for NHL? - NCI
